Download in electronic PDF format for $25



Search the Complete Journal Archives

Skin Penetration and Antinociception of Topical Gabapentin Formulations

Author(s):  Bryson Evan,Asbill Scott,Sweitzer Sarah

Issue:  Nov/Dec 2014 - Volume 18, Number 6
View All Articles in Issue

Abstract:  Chronic pain affects greater than 116 million Americans each year. Even with the best pain management approaches, many chronic pain patients still suffer from moderate to severe pain. An alternative therapy to treat chronic pain includes compounded topical formulations of common analgesics. Compounded dosage forms of gabapentin are commonly used for pain management, however, the penetration and efficacy of gabapentin in these compounded topical formulations has not been fully studied. In this study, the transdermal penetration of gabapentin was studied in Franz diffusion cells using porcine skin. Gabapentin was compounded in two commercially available bases; Lipobase, Lipoderm, and a standard poloxamer lecithin organogel. The penetration and retention of gabapentin in the skin was dependent upon the base. The most rapid and greatest penetration and retention of gabapentin in the skin occurred with a poloxamer lecithin organogel base. Lipobase and Lipoderm bases produced slow and smaller penetration and retention of gabapentin as compared to poloxamer lecithin organogel base. Gabapentin 1% and 5% compounded in Lipoderm were tested in the in vivo preclinical formalin pain model. Topical 5% gabapentin produced a similar reduction in nociception in both Phase 1 and Phase 2 of the formalin response as systemic subcutaneous gabapentin (100 mg/kg). Topical 1% gabapentin reduced Phase 2, but not Phase 1 formalin-induced nociceptive behaviors. These findings suggest that topical administration of gabapentin may produce local antinociception.

Related Keywords: Evan Bryson, Scott Asbill, PhD, Sarah Sweitzer, PhD, gabapentin, chronic pain, topical preparations, transdermal penetration, Franz diffusion cells, porcine skin permeation, skin permeability, Lipobase, Lipoderm, poloxamer lecithin organogel, in vivo preclinical formalin pain model, nociception, antinociception, hamsters

Related Categories: EXCIPIENTS, PAIN MANAGEMENT, PEER-REVIEWED, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Skin Penetration and Antinociception of Topical Gabapentin Formulations Bryson Evan, Asbill Scott, Sweitzer Sarah Nov/Dec 2014 504-511 Buy
Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations Bryson Evan, Hartman Rachel, Arnold John, Gorman Greg, Sweitzer Sarah.Asbill Scott Mar/Apr 2015 161-166 Buy
In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations Heustess Allie, Asbill Scott, Eagerton David, Arnold John Nov/Dec 2014 512-515 Buy
Veterinary Transdermal Medications: A to Z Davidson Gigi S Mar/Apr 2003 106 Buy
Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time Heustess Allie, Spigener Shuler, Sweitzer Sarah, Romero-Sandoval Alfonso, Asbill Scott Mar/Apr 2015 167-173 Buy
Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott May/Jun 2013 247-253 Buy
The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel Arnold John J, Asbill Scott Nov/Dec 2009 569-571 Buy
Compounded Pain Formulations: What is the Evidence? Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso Jul/Aug 2014 278-286 Buy
Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth May/Jun 2014 256-261 Buy
Basics of Compounding for Dry-Skin Conditions Allen Loyd V Jr Nov/Dec 2003 460-463 View Sample